Stocks and Finance

Dendreon

Dendreon 5/23/2012

14:02 : Dendreon falls as analyst starts coverage - NEW YORK (AP) -- Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors....
Source : usnews-com

Dendreon 5/17/2012

10:24 : Dendreon shares drop on SEC probe - BOSTON (MarketWatch) -- Shares of Dendreon Corp. slid 8% to $7.91 on Thursday following news that the Securities and Exchange Commission has launched a formal investigation into the biotech company. In a recent regulatory filing, Dendreon ...
Source : marketwatch-com

Dendreon 5/16/2012

16:59 : Shares of Dendreon (DNDN) are trading lower after hours on unconfirmed ... - Shares of Dendreon (DNDN) are trading lower after hours on unconfirmed rumors that the SEC has opened a probe on the company's disclosures. While the company did disclose a formal Securities ...
Source : seekingalpha-com

Dendreon 5/8/2012

12:37 : Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, ... - by Justin Kuepper Most profits (and losses) are generated when markets are trending--so predicting trends correctly can be extremely helpful. Many traders use candlestick charts to help them locate such trends amid often erratic market ...
Source : 247wallst-com
11:17 : Dendreon tumbles on sales report - BOSTON (MarketWatch) -- Shares of Dendreon Corp. tumbled 22% to $9.08 on Tuesday, the day after the biotech firm issued a weaker-than-expected earnings report. Analysts at Leerink Swann on Tuesday cut their rating of the stock to market ...
Source : marketwatch-com

Dendreon 5/7/2012

16:20 : Dendreon, When 200% Sales Growth Is Not Enough (DNDN) - SAN FRANCISCO (MarketWatch) -- U.S. stocks ended close to the flatline on Monday, as unease over the outcome of European elections kept a damper on sentiment, though much of that outcome was priced in. The Dow Jones Industrial ...
Source : 247wallst-com
16:14 : More on Dendreon (DNDN): Q1 EPS beats on an adjusted basis but misses ... - More on Dendreon (DNDN): Q1 EPS beats on an adjusted basis but misses on a net basis due to one-time severance expenses. Net product revenue for the quarter was $82M, boosted by higher sales of Provenge, compared to $27M for the same prior ...
Source : seekingalpha-com

Dendreon 4/12/2012

09:14 : Citi cuts its price target on Dendreon ([[DNDN]] +0.3%) to $10 from $14 ... - Citi cuts its price target on Dendreon (DNDN +0.3%) to $10 from $14 as the firm's Yaron Werber sees a "significant" threat to Provenge from rivals over the next couple of years. (Previous: Citi on DNDN) Post your comment!
Source : seekingalpha-com

Dendreon 3/8/2012

10:05 : Deutsche Bank sticks to its guns on Dendreon ([[DNDN]] -16.1%) despite ... - Deutsche Bank sticks to its guns on Dendreon (DNDN -16.1%) despite the sharp selloff off of news that Johnson & Johnson's prostate cancer drug is a go. Analysts with Deutsche not only maintain a Buy rating while keeping ...
Source : seekingalpha-com

Dendreon 2/27/2012

12:31 : Dendreon plunges 18% on sales report - BOSTON (MarketWatch) -- Shares of Dendreon Corp. plunged 18% to $12.12 on Monday after it issued a weaker-than-expected quarterly sales report for its prostate cancer therapy Provenge. Dendreon shares have been on a roll ...
Source : marketwatch-com

Dendreon 2/22/2012

10:57 : Forbes Earnings Preview: Dendreon - Expectations have dropped for Dendreon's (DNDN) fourth quarter results in the month leading up to the company's earnings announcement slated for Monday, February 27, 2012. The consensus analyst estimate has dropped from a loss of 33 cents a share to ...
Source : forbes-com

Dendreon 1/6/2012

17:20 : NewsWatch: Alcoa, Dendreon may see active after-hours trade - Alcoa Inc. may be among the actively-traded stocks Friday evening, ahead of the aluminum giant’s quarterly financial results due Monday. Dendreon Corp., Jazz Pharmaceuticals, Regeneron, AutoNation ...
Source : marketwatch-com
12:37 : Dendreon rallies for second day - BOSTON (MarketWatch) -- Shares of Dendreon Corp. shot up for the second day on Friday, climbing 11% to $11.73 after shooting up nearly 50% the previous session. On Thursday, Dendreon reported stronger-than-expected sales ...
Source : marketwatch-com
12:13 : Dendreon shares climb after sales info release - Shares of Dendreon Corp. jumped again on Friday, a day after the drug developer said sales of its prostate-cancer therapy Provenge kept growing in the fourth quarter....
Source : usnews-com

Dendreon 1/5/2012

10:41 : Dendreon soars 50% on business update - BOSTON (MarketWatch) -- Shares of biotech group Dendreon Corp. soared nearly 50% to $11.06 after it reported better-than-expected sales of its prostate cancer therapy Provenge. Dendreon attributed the boost to improved insurance ...
Source : marketwatch-com

Dendreon 12/6/2011

16:13 : Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK) - Senate Minority Leader Mitch McConnell rejected the latest Democratic proposal to extend the payroll-tax holiday, pushing off the prospect of reaching a quick compromise on the tax break.
Source : 247wallst-com

Dendreon 11/17/2011

23:24 : Dendreon Buyout, How Imminent? - NEW YORK (TheStreet ) - NovaGold's radical management shakeup and restructuring could set the stage for Barrick Gold to launch a takeover bid. #xD; #xD; Gregory Lang, former president of Barrick Gold North America, ...
Source : 247wallst-com

Dendreon 11/16/2011

13:24 : Shares in biotech Dendreon ([[DNDN]] +9.7%) are halted after hitting circu - Shares in biotech Dendreon (DNDN +9.7%) are halted after hitting circuit breakers to the upside. Update at 1:18: Shares back online now, +5.7%. No news has yet hit giving a reason for the move. Post your comment!
Source : seekingalpha-com

Dendreon 11/8/2011

14:46 : Management still seems to have faith in Dendreon ([[DNDN]] +11.1%) despite - Management still seems to have faith in Dendreon (DNDN +11.1%) despite recent setbacks (I, II) related to its Provenge prostate cancer treatment, as shares rally on news that the CFO and a Director just bought 32,530 shares at $6.66-$6.68, ...
Source : seekingalpha-com

Dendreon 11/3/2011

11:40 : Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN) - New technology usually comes with its share of consumer concerns. It's no surprise that urban legends and myths have proliferated about the new EMV chip credit cards. Here are a few of the most common, along with our expert opinion as to their veracity:
Source : 247wallst-com
09:45 : Dendreon plunges on tepid Provenge sales report - BOSTON (MarketWatch) -- Shares of Dendreon Corp. plunged 35% to $6.81 on Thursday, the day after it reported weaker-than-expected sales for its new prostate cancer therapy Provenge. Early Thursday, analysts at Goldman Sachs|Goldman ...
Source : marketwatch-com

Dendreon 11/2/2011

17:18 : Shares of Dendreon (DNDN) are getting hammered in the post-trading session - Shares of Dendreon (DNDN) are getting hammered in the post-trading session, despite reporting FQ4 earnings that largely beat estimates. The company forecasts only modest sales growth for Provenge, its blockbuster prostate ...
Source : seekingalpha-com

Dendreon 10/4/2011

11:10 : Shares of Dendreon (DNDN) gain 10%, unfazed by an initiation from Imperial - Shares of Dendreon (DNDN) gain 10%, unfazed by an initiation from Imperial Capital at Underperform. The company is in the spotlight this week after Ralph Steinman - whose work serves as an inspiration to DNDN's prostate cancer therapy ...
Source : seekingalpha-com

Dendreon 9/9/2011

08:14 : Ahead of the Bell: Dendreon cuts deemed necessary - Dendreon Corp.'s announcement that it will cut 500 jobs was a necessary step, but long-term concerns remain regarding the drug company's only marketed product, the prostate cancer therapy Provenge, according to a Citi analyst...
Source : usnews-com
08:13 : Pharma News: J&J, Dendreon, Myrexis - Keep an eye on shares of Johnson & Johnson (JNJ) today. An advisory panel to the Food & Drug Administration gave its okay to a blood thinner J&J developed with Bayer, Xarelto, suggesting that the agency approve the drug. The ...
Source : forbes-com

Dendreon 9/8/2011

17:09 : Dendreon (DNDN) announces a restructuring including a reduction of ~500 ... - Dendreon (DNDN) announces a restructuring including a reduction of ~500 jobs, and the departure of COO Hans Bishop. The company is looking to trim expenses in light of diminished sales expectations for its high-priced Provenge prostate ...
Source : seekingalpha-com

Dendreon 9/6/2011

07:41 : Dendreon (DNDN) ends its development and supply agreement with GlaxoSmithK - Dendreon (DNDN) ends its development and supply agreement with GlaxoSmithKline (GSK) on Dendreon's prostate cancer vaccine Provenge, citing "unforeseen delays and implementation difficulties." DNDN shares have plunged nearly 70% after ...
Source : seekingalpha-com

Dendreon 8/18/2011

19:06 : Biotech Stocks: 3 biotech stocks battle the ‘Dendreon Effect’ - Dendreon Corp.’s tepid sales report has not only chilled trading in the company’s once-hot stock but has also managed to frost investors in three other biotechs: Savient Pharmaceuticals, Human Genome Sciences|Human ...
Source : marketwatch-com

Dendreon 8/15/2011

13:58 : Shares of Dendreon ([[DNDN]] +20.3%) recover nicely on volume 2X normal ... - Shares of Dendreon (DNDN +20.3%) recover nicely on volume 2X normal after a recent 70% loss in share value - related to the firm's devastating result with its Provenge cancer treatment - looks overdone to investors. Post your comment!
Source : seekingalpha-com

Dendreon 8/4/2011

15:46 : Mixed options trading ensues on Dendreon disaster - DNDN - Dendreon Corp. – Investors stormed Dendreon Corp. options this morning with shares hemorrhaging uncontrollably during the first 90 minutes of trade. The stock dropped as much as 68.0% to land an intraday low of $11.34. ...
Source : fxstreet-com
actualidad Dendreon -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts